First patient dosed in combination trial of OBT076 and CPI Balstilimab – Oxford BioTherapeutics

We are pleased to announce that the first patient has been dosed in a Phase 1b combination trial evaluating OBT076 and Agenus’ PD1 checkpoint inhibitor Balstilimab.

OBT076 is a CD205-targeting antibody-drug conjugate (ADC) being evaluated in patients with advanced solid tumors and demonstrates a potential dual mechanism of action to re-engage the immune system and make more patients eligible for immunotherapies and checkpoint inhibitors.

We have also begun recruitment in Europe into the expansion cohorts of the Phase 1 trial investigating the safety, tolerability and pharmacokinetic profile of OBT076 as a monotherapy.

Find out more: https://lnkd.in/eTjxd5_c

Source: Oxford BioTherapeutics/Linkedin